Degradation of HER2 receptor through hypericin-mediated photodynamic therapy

Photochemistry and Photobiology
Ján KovalPeter Fedorocko

Abstract

Current treatment of breast cancer is often affected by resistance to therapeutics, for which the human epidermal growth factor receptor 2 (HER2) may be responsible. Here, we report for the first time the use of hypericin-mediated photodynamic therapy (HY-PDT) in combination with a selective HER2 inhibitor (AG 825) on SKBR-3, a HER2 overexpressing human breast adenocarcinoma cell line. The results demonstrate that HY-PDT is able to degrade HER2 with an impact on its signaling cascade. Combination with AG 825 resulted in increased apoptosis induction, total degradation of HER2 and inhibition of colony formation. Downregulation of HSP90, Mcl-1, Bcl-xL and upregulation of Bax was also observed. This knowledge provides the basis for the possible application of HY-PDT in preclinical and clinical models of breast cancer treatment.

References

Jun 24, 1998·Journal of the National Cancer Institute·T J DoughertyQ Peng
Nov 7, 2001·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·I CavargaP Miskovský
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Athanassios ArgirisMichael P DiGiovanna
Mar 3, 2004·Annals of Surgical Oncology·Rosa E CuencaGordon H Downie
Jul 29, 2005·International Journal of Cancer. Journal International Du Cancer·Eriko TokunagaYoshihiko Maehara
Dec 15, 2005·Journal of Cell Science·Mads LerdrupBo van Deurs
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth S HensonSpencer B Gibson
Jun 3, 2006·Photochemistry and Photobiology·Veronika SackováJán Kleban
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 6, 2007·Cancer Research·Elah PickHarriet M Kluger
Dec 7, 2007·The Journal of Biological Chemistry·Katerina SideraEvangelia Patsavoudi
Sep 6, 2008·Journal of Photochemistry and Photobiology. B, Biology·Ján KlebanPeter Fedorocko
Nov 15, 2008·Cancer Treatment Reviews·Dorte Lisbet NielsenClaus Kamby

❮ Previous
Next ❯

Citations

Aug 27, 2013·Biochemical Pharmacology·Marie-Hélène TeitenMarc Diederich
Jun 27, 2015·Journal of Photochemistry and Photobiology. B, Biology·A PopovicL M Davids
May 21, 2016·Frontiers in Plant Science·Zuzana JendželovskáPeter Fedoročko
Jan 1, 2011·Cancers·Pawel MrozMichael R Hamblin
Nov 10, 2011·Pharmaceuticals·Peter SolárPeter Fedoročko
Jul 10, 2019·International Journal of Molecular Sciences·Manuel Gallardo-VillagránBruno Therrien
Dec 24, 2010·Radiation Research·Peter SolárPeter Fedoročko

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.